Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Eleftherios Mylonakis, PH.D., M.D.

TitleVisiting Professor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Infectious Disease, GRJ 505
55 Fruit St
Boston MA 02114
Phone617/726-3812

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Ziakas PD, Anagnostou T, Mylonakis E. The Prevalence and Significance of Methicillin-Resistant Staphylococcus aureus Colonization at Admission in the General ICU Setting: A Meta-Analysis of Published Studies*. Crit Care Med. 2014 Feb; 42(2):433-44.
    View in: PubMed
  2. Kourbeti IS, Mylonakis E. Fungal central nervous system infections: prevalence and diagnosis. Expert Rev Anti Infect Ther. 2014 Feb; 12(2):265-73.
    View in: PubMed
  3. Anagnostou T, Arvanitis M, Kourkoumpetis TK, Desalermos A, Carneiro HA, Mylonakis E. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine (Baltimore). 2014 Jan; 93(1):19-32.
    View in: PubMed
  4. Ziakas PD, Prodromou ML, El Khoury J, Zintzaras E, Mylonakis E. The Role of TLR4 896 A>G and 1196 C>T in Susceptibility to Infections: A Review and Meta-Analysis of Genetic Association Studies. PLoS One. 2013; 8(11):e81047.
    View in: PubMed
  5. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, Coleman JJ, Mylonakis E. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013 Nov; 92(6):305-16.
    View in: PubMed
  6. Arvanitis M, Li DD, Lee K, Mylonakis E. Apoptosis in C. elegans: lessons for cancer and immunity. Front Cell Infect Microbiol. 2013; 3:67.
    View in: PubMed
  7. Chibebe Junior J, Sabino CP, Tan X, Junqueira JC, Wang Y, Fuchs BB, Jorge AO, Tegos GP, Hamblin MR, Mylonakis E. Selective photoinactivation of Candida albicans in the non-vertebrate host infection model Galleria mellonella. BMC Microbiol. 2013; 13:217.
    View in: PubMed
  8. Ziakas PD, Thapa R, Rice LB, Mylonakis E. Trends and Significance of VRE Colonization in the ICU: A Meta-Analysis of Published Studies. PLoS One. 2013; 8(9):e75658.
    View in: PubMed
  9. Li DD, Xu Y, Zhang DZ, Quan H, Mylonakis E, Hu DD, Li MB, Zhao LX, Zhu LH, Wang Y, Jiang YY. Fluconazole Assists Berberine To Kill Fluconazole-Resistant Candida albicans. Antimicrob Agents Chemother. 2013 Dec; 57(12):6016-27.
    View in: PubMed
  10. Ziakas PD, Karsaliakos P, Prodromou ML, Mylonakis E. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. Biomarkers. 2013 Nov; 18(7):625-31.
    View in: PubMed
  11. Arvanitis M, Glavis-Bloom J, Mylonakis E. C. elegans for anti-infective discovery. Curr Opin Pharmacol. 2013 Oct; 13(5):769-74.
    View in: PubMed
  12. Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, Mylonakis E, Ballen KK. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1190-6.
    View in: PubMed
  13. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wellman P, Mylonakis E, Lowery TJ. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013 Apr 24; 5(182):182ra54.
    View in: PubMed
  14. Arvanitis M, Glavis-Bloom J, Mylonakis E. Invertebrate models of fungal infection. Biochim Biophys Acta. 2013 Sep; 1832(9):1378-83.
    View in: PubMed
  15. Chibebe Junior J, Fuchs BB, Sabino CP, Junqueira JC, Jorge AO, Ribeiro MS, Gilmore MS, Rice LB, Tegos GP, Hamblin MR, Mylonakis E. Photodynamic and Antibiotic Therapy Impair the Pathogenesis of Enterococcus faecium in a Whole Animal Insect Model. PLoS One. 2013; 8(2):e55926.
    View in: PubMed
  16. Cunha CB, Varughese CA, Mylonakis E. Antimicrobial stewardship programs (ASPs): The devil is in the details. Virulence. 2013 Feb 15; 4(2):147-9.
    View in: PubMed
  17. Prates RA, Fuchs BB, Mizuno K, Naqvi Q, Kato IT, Ribeiro MS, Mylonakis E, Tegos GP, Hamblin MR. Effect of Virulence Factors on the Photodynamic Inactivation of Cryptococcus neoformans. PLoS One. 2013; 8(1):e54387.
    View in: PubMed
  18. Kato IT, Prates RA, Sabino CP, Fuchs BB, Tegos GP, Mylonakis E, Hamblin MR, Ribeiro MS. Antimicrobial Photodynamic Inactivation Inhibits Candida albicans Virulence Factors and Reduces In Vivo Pathogenicity. Antimicrob Agents Chemother. 2013 Jan; 57(1):445-51.
    View in: PubMed
  19. Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore). 2012 Nov; 91(6):328-36.
    View in: PubMed
  20. Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R, Monteagudo C, Mylonakis E, Köhler JR, Lopez Ribot JL. Physiologic Expression of the Candida albicans Pescadillo Homolog Is Required for Virulence in a Murine Model of Hematogenously Disseminated Candidiasis. Eukaryot Cell. 2012 Dec; 11(12):1552-6.
    View in: PubMed
  21. Suzuki T, Campbell J, Kim Y, Swoboda JG, Mylonakis E, Walker S, Gilmore MS. Wall teichoic acid protects Staphylococcus aureus from inhibition by Congo red and other dyes. J Antimicrob Chemother. 2012 Sep; 67(9):2143-51.
    View in: PubMed
  22. Kim Y, Mylonakis E. Caenorhabditis elegans immune conditioning with the probiotic bacterium Lactobacillus acidophilus strain NCFM enhances gram-positive immune responses. Infect Immun. 2012 Jul; 80(7):2500-8.
    View in: PubMed
  23. Muhammed M, Feldmesser M, Shubitz LF, Lionakis MS, Sil A, Wang Y, Glavis-Bloom J, Lewis RE, Galgiani JN, Casadevall A, Kontoyiannis DP, Mylonakis E. Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus. Virulence. 2012 May 1; 3(3):329-38.
    View in: PubMed
  24. Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St Denis TG, Ribeiro MS, Mylonakis E, Hamblin MR, Tegos GP. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol. 2012; 3:120.
    View in: PubMed
  25. Desalermos A, Kourkoumpetis TK, Mylonakis E. Update on the epidemiology and management of cryptococcal meningitis. Expert Opin Pharmacother. 2012 Apr; 13(6):783-9.
    View in: PubMed
  26. Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012 May; 54(9):1322-31.
    View in: PubMed
  27. Desalermos A, Fuchs BB, Mylonakis E. Selecting an invertebrate model host for the study of fungal pathogenesis. PLoS Pathog. 2012 Feb; 8(2):e1002451.
    View in: PubMed
  28. Muhammed M, Fuchs BB, Wu MP, Breger J, Coleman JJ, Mylonakis E. The role of mycelium production and a MAPK-mediated immune response in the C. elegans-Fusarium model system. Med Mycol. 2012 Jul; 50(5):488-96.
    View in: PubMed
  29. Glavis-Bloom J, Muhammed M, Mylonakis E. Of model hosts and man: using Caenorhabditis elegans, Drosophila melanogaster and Galleria mellonella as model hosts for infectious disease research. Adv Exp Med Biol. 2012; 710:11-7.
    View in: PubMed
  30. Muhammed M, Coleman JJ, Mylonakis E. Caenorhabditis elegans: a nematode infection model for pathogenic fungi. Methods Mol Biol. 2012; 845:447-54.
    View in: PubMed
  31. Carneiro HA, Mavrakis A, Mylonakis E. Candida peritonitis: an update on the latest research and treatments. World J Surg. 2011 Dec; 35(12):2650-9.
    View in: PubMed
  32. Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, Chiba A, Fuchs BB, Mylonakis E, Besra GS, Levitz SM, Brigl M, Brenner MB. Innate recognition of cell wall ß-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe. 2011 Nov 17; 10(5):437-50.
    View in: PubMed
  33. Junqueira JC, Fuchs BB, Muhammed M, Coleman JJ, Suleiman JM, Vilela SF, Costa AC, Rasteiro VM, Jorge AO, Mylonakis E. Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol. 2011; 11:247.
    View in: PubMed
  34. Riedmann EM, Sharpe S, Mylonakis E. Virulence: The first two years. Virulence. 2011 Nov-Dec; 2(6):491-2.
    View in: PubMed
  35. Coleman JJ, Muhammed M, Kasperkovitz PV, Vyas JM, Mylonakis E. Fusarium pathogenesis investigated using Galleria mellonella as a heterologous host. Fungal Biol. 2011 Dec; 115(12):1279-89.
    View in: PubMed
  36. Coleman JJ, Ghosh S, Okoli I, Mylonakis E. Antifungal activity of microbial secondary metabolites. PLoS One. 2011; 6(9):e25321.
    View in: PubMed
  37. Mylonakis E, Muse VV, Mino-Kenudson M. Case records of the Massachusetts General Hospital. Case 28-2011. A 74-year-old man with pemphigus vulgaris and lung nodules. N Engl J Med. 2011 Sep 15; 365(11):1043-50.
    View in: PubMed
  38. Pukkila-Worley R, Ausubel FM, Mylonakis E. Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses. PLoS Pathog. 2011 Jun; 7(6):e1002074.
    View in: PubMed
  39. Kim Y, Mylonakis E. Killing of Candida albicans filaments by Salmonella enterica serovar Typhimurium is mediated by sopB effectors, parts of a type III secretion system. Eukaryot Cell. 2011 Jun; 10(6):782-90.
    View in: PubMed
  40. Shenoy ES, Mylonakis E, Hurtado RM, Venna N. Natalizumab and HSV meningitis. J Neurovirol. 2011 Jun; 17(3):288-90.
    View in: PubMed
  41. Muhammed M, Coleman JJ, Carneiro HA, Mylonakis E. The challenge of managing fusariosis. Virulence. 2011 Mar-Apr; 2(2):91-6.
    View in: PubMed
  42. Anastassopoulou CG, Fuchs BB, Mylonakis E. Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des. 2011; 17(13):1225-33.
    View in: PubMed
  43. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore). 2011 Jan; 90(1):69-80.
    View in: PubMed
  44. Mylonakis E. The need to redefine antimicrobial drug discovery. Curr Pharm Des. 2011; 17(13):1223-4.
    View in: PubMed
  45. Ziakas PD, Kourbeti IS, Voulgarelis M, Mylonakis E. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther. 2010 Dec; 32(14):2316-36.
    View in: PubMed
  46. Spanakis EK, Kourkoumpetis TK, Livanis G, Peleg AY, Mylonakis E. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin Proc. 2010 Dec; 85(12):1073-9.
    View in: PubMed
  47. Campbell J, Singh AK, Santa Maria JP, Kim Y, Brown S, Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem Biol. 2011 Jan 21; 6(1):106-16.
    View in: PubMed
  48. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence. 2010 Nov-Dec; 1(6):475-82.
    View in: PubMed
  49. Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, Mylonakis E. The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia. 2011 Feb; 171(2):85-91.
    View in: PubMed
  50. Fuchs BB, Bishop LR, Kovacs JA, Mylonakis E. Galleria mellonella are resistant to Pneumocystis murina infection. Mycopathologia. 2011 Apr; 171(4):273-7.
    View in: PubMed
  51. Kourkoumpetis T, Manolakaki D, Velmahos G, Chang Y, Alam HB, De Moya MM, Sailhamer EA, Mylonakis E. Candida infection and colonization among non-trauma emergency surgery patients. Virulence. 2010 Sep-Oct; 1(5):359-66.
    View in: PubMed
  52. Manolakaki D, Velmahos G, Kourkoumpetis T, Chang Y, Alam HB, De Moya MM, Mylonakis E. Candida infection and colonization among trauma patients. Virulence. 2010 Sep-Oct; 1(5):367-75.
    View in: PubMed
  53. Pukkila-Worley R, Mylonakis E. From the outside in and the inside out: Antifungal immune responses in Caenorhabditis elegans. Virulence. 2010 May-Jun; 1(3):111-2.
    View in: PubMed
  54. Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial-fungal interactions. Nat Rev Microbiol. 2010 May; 8(5):340-9.
    View in: PubMed
  55. Coleman JJ, Okoli I, Tegos GP, Holson EB, Wagner FF, Hamblin MR, Mylonakis E. Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol. 2010 Mar 19; 5(3):321-32.
    View in: PubMed
  56. Fuchs BB, Eby J, Nobile CJ, El Khoury JB, Mitchell AP, Mylonakis E. Role of filamentation in Galleria mellonella killing by Candida albicans. Microbes Infect. 2010 Jun; 12(6):488-96.
    View in: PubMed
  57. Dai T, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med. 2010 Jan; 42(1):38-44.
    View in: PubMed
  58. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009 Dec 15; 49(12):1883-9.
    View in: PubMed
  59. Carneiro HA, Mylonakis E. Google trends: a web-based tool for real-time surveillance of disease outbreaks. Clin Infect Dis. 2009 Nov 15; 49(10):1557-64.
    View in: PubMed
  60. Okoli I, Coleman JJ, Tampakakis E, Tempakakis E, An WF, Holson E, Wagner F, Conery AL, Larkins-Ford J, Wu G, Stern A, Ausubel FM, Mylonakis E. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One. 2009; 4(9):e7025.
    View in: PubMed
  61. Fuchs BB, Mylonakis E. Our paths might cross: the role of the fungal cell wall integrity pathway in stress response and cross talk with other stress response pathways. Eukaryot Cell. 2009 Nov; 8(11):1616-25.
    View in: PubMed
  62. Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E. Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model. Eukaryot Cell. 2009 Nov; 8(11):1750-8.
    View in: PubMed
  63. Ngamskulrungroj P, Himmelreich U, Breger JA, Wilson C, Chayakulkeeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, Mylonakis E, Meyer W, Perfect JR. The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun. 2009 Oct; 77(10):4584-96.
    View in: PubMed
  64. Coleman JJ, Mylonakis E. Efflux in fungi: la pièce de résistance. PLoS Pathog. 2009 Jun; 5(6):e1000486.
    View in: PubMed
  65. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica. 2009 Jul; 94(7):998-1005.
    View in: PubMed
  66. Peleg AY, Lasalvia MT, Mylonakis E, Silveira FP. Prophylaxis against pulmonary viral and fungal infections in solid organ transplant recipients. Curr Infect Dis Rep. 2009 May; 11(3):209-15.
    View in: PubMed
  67. Coleman JJ, Mylonakis E. The tangled web of signaling in innate immunity. Cell Host Microbe. 2009 Apr 23; 5(4):313-5.
    View in: PubMed
  68. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother. 2009 Jun; 53(6):2605-9.
    View in: PubMed
  69. Tampakakis E, Peleg AY, Mylonakis E. Interaction of Candida albicans with an intestinal pathogen, Salmonella enterica serovar Typhimurium. Eukaryot Cell. 2009 May; 8(5):732-7.
    View in: PubMed
  70. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, Puckett L, Tai MF, Stewart CR, Pukkila-Worley R, Hickman SE, Moore KJ, Calderwood SB, Hacohen N, Luster AD, El Khoury J. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med. 2009 Mar 16; 206(3):637-53.
    View in: PubMed
  71. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis. 2009 Feb 15; 199(4):532-6.
    View in: PubMed
  72. Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2818-23.
    View in: PubMed
  73. Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC, Mylonakis E. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14585-90.
    View in: PubMed
  74. Thakur JK, Arthanari H, Yang F, Pan SJ, Fan X, Breger J, Frueh DP, Gulshan K, Li DK, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Näär AM. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature. 2008 Apr 3; 452(7187):604-9.
    View in: PubMed
  75. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother. 2008 Mar; 9(4):551-60.
    View in: PubMed
  76. Tampakakis E, Okoli I, Mylonakis E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protoc. 2008; 3(12):1925-31.
    View in: PubMed
  77. Mylonakis E. Galleria mellonella and the study of fungal pathogenesis: making the case for another genetically tractable model host. Mycopathologia. 2008 Jan; 165(1):1-3.
    View in: PubMed
  78. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 2007 Jul 27; 3(7):e101.
    View in: PubMed
  79. Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E. Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother. 2007 Aug; 51(8):2929-36.
    View in: PubMed
  80. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun; 8(8):1167-78.
    View in: PubMed
  81. Fan W, Idnurm A, Breger J, Mylonakis E, Heitman J. Eca1, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, is involved in stress tolerance and virulence in Cryptococcus neoformans. Infect Immun. 2007 Jul; 75(7):3394-405.
    View in: PubMed
  82. Fuchs BB, Tang RJ, Mylonakis E. The temperature-sensitive role of Cryptococcus neoformans ROM2 in cell morphogenesis. PLoS One. 2007; 2(4):e368.
    View in: PubMed
  83. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, Bose I, Kim MJ, Skau C, Yang S, Sefko JA, Osumi M, Latge JP, Mylonakis E, Doering TL. Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol. 2007 Mar; 63(5):1385-98.
    View in: PubMed
  84. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect. 2007 May; 9(6):729-34.
    View in: PubMed
  85. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 2007 Feb; 3(2):e18.
    View in: PubMed
  86. Maadani A., Fox KA, Mylonakis E, Garsin DA. . Enterococcus faecalis mutations affecting virulence in the C. elegans model host. Infect Immun. 2007; 75:2634-7.
  87. Ausubel FM, Calderwood SB, Garsin DA, Mylonakis E, Sifri CD. . Virulence genes of Enterococcus faecalis, identified with the use of nematode and mammalian models. 2007.
  88. Ausubel FM, Calderwood SB, Mylonakis E. . Use of Caenorhabditis elegans for the study of virulence factors in anaerobic and facultatively anaerobic organisms. 2007.
  89. Co-author with Dr. S.L. Gorbach . Electronic Manual on “Treatment of Infectious Diseases”. 2007.
  90. Ausubel FM, Calderwood SB, Diener A, Heard J, Jander G, Mylonakis E, Plotnikova J, Rahme LG, Ruvkun GB, Sifri CD, Tan M-W. . Methods of screening compounds useful for prevention of infection or pathogenicity. 2007.
  91. Ausubel FM, Breger J, Moy T, Mylonakis E. . Cafeic acid phenethyl esters for the treatment of fungal infections. Ref. #. 2007.
  92. Fan W, Idnurm A, Breger J, Mylonakis E, Heitman J. Ecal, a sarco/Endoplasmic reticulum Ca2+-ATPase, is involved in stress tolerance and virulence in Cryptococcus neoformans. Infect Immun. 2007; (in press).
  93. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect (in press). 2007.
  94. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, Bose I, Kim M-J, Skau C, Yang S, Sefko JA, Osumi M, Latge J-P, Mylonakis E, Doering TL . Loss of cell wall alpha-1,3-glucan affects Cryptococcus neoformansfrom ultrastructure to virulence. Mol Microbiol. 2007; 63:1385-98.
  95. Aperis G, Myriounis N, Spanakis EK, Mylonakis E. Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs. 2006 Nov; 15(11):1319-36.
    View in: PubMed
  96. Petzold EW, Himmelreich U, Mylonakis E, Rude T, Toffaletti D, Cox GM, Miller JL, Perfect JR. Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun. 2006 Oct; 74(10):5877-87.
    View in: PubMed
  97. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006 Oct 15; 43(8):1060-8.
    View in: PubMed
  98. Ngamskulrungroj P, Himmelreich U, Breger J, Chayakulkeeree M, Toffaletti D Mylonakis E, Meyer W, Perfect J. . The characterization of the trehalose synthesis pathway in Cryptococcus gattii. XXIIIrd International Conference on Yeast Genetics and Molecular Biology. 2006.
  99. Fuchs BB, Mylonakis E. Using non-mammalian hosts to study fungal virulence and host defense. Curr Opin Microbiol. 2006 Aug; 9(4):346-51.
    View in: PubMed
  100. London R, Orozco BS, Mylonakis E. The pursuit of cryptococcal pathogenesis: heterologous hosts and the study of cryptococcal host-pathogen interactions. FEMS Yeast Res. 2006 Jun; 6(4):567-73.
    View in: PubMed
  101. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006 Jun; 15(6):579-602.
    View in: PubMed
  102. Mylonakis E, Calderwood SB, Ausubel FM. . Heterologous hosts and the evolution and study of fungal pathogenesis. Molecular Principles of Fungal Pathogenesis. 2006.
  103. Tang RJ, Breger J, Idnurm A, Gerik KJ, Lodge JK, Heitman J, Calderwood SB, Mylonakis E. Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a Caenorhabditis elegans progeny-based approach. Infect Immun. 2005 Dec; 73(12):8219-25.
    View in: PubMed
  104. Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK, Giles SS, Mitchell TG, Casadevall A, Perfect JR, Heitman J. Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun. 2005 Aug; 73(8):4922-33.
    View in: PubMed
  105. Mylonakis E, Aballay A. Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect Immun. 2005 Jul; 73(7):3833-41.
    View in: PubMed
  106. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun. 2005 Jul; 73(7):3842-50.
    View in: PubMed
  107. Tang RJ, Breger J, Idnurm A, Gerik K, Lodge JK, Heitman J, Calderwood SB, Mylonakis E . Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a C. elegans progeny-based approach. 2005; 73: 8219-25. Infect Immun. 2005; 73:8219-25.
  108. Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, Ausubel FM, Heitman J, Calderwood SB. Cryptococcus neoformans Kin1 protein kinase homologue, identified through a Caenorhabditis elegans screen, promotes virulence in mammals. Mol Microbiol. 2004 Oct; 54(2):407-19.
    View in: PubMed
  109. Moy TI, Mylonakis E, Calderwood SB, Ausubel FM. Cytotoxicity of hydrogen peroxide produced by Enterococcus faecium. Infect Immun. 2004 Aug; 72(8):4512-20.
    View in: PubMed
  110. Bhabhra R, Miley MD, Mylonakis E, Boettner D, Fortwendel J, Panepinto JC, Postow M, Rhodes JC, Askew DS. Disruption of the Aspergillus fumigatus gene encoding nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. Infect Immun. 2004 Aug; 72(8):4731-40.
    View in: PubMed
  111. Engelbert M, Mylonakis E, Ausubel FM, Calderwood SB, Gilmore MS. Contribution of gelatinase, serine protease, and fsr to the pathogenesis of Enterococcus faecalis endophthalmitis. Infect Immun. 2004 Jun; 72(6):3628-33.
    View in: PubMed
  112. Apidianakis Y, Rahme LG, Heitman J, Ausubel FM, Calderwood SB, Mylonakis E. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryot Cell. 2004 Apr; 3(2):413-9.
    View in: PubMed
  113. Moy T, Mylonakis E, Calderwood SB, Ausubel FM. . Cytotoxicity from hydrogen peroxide produced by Enterococcus faecium. Infect Immun. 2004; 72:4512-20.
  114. Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, Ausubel FM, Heitman J, Calderwood SB. . Cryptococcus neoformans Kin1 protein kinase homolog, identified through a C. elegans screen, promotes virulence in mammals. 2004; 54:407-19. Mol Microbiol. 2004; 54:407-19.
  115. Mylonakis E, Ausubel FM, Tang RJ, Calderwood SB. The art of serendipity: killing of Caenorhabditis elegans by human pathogens as a model of bacterial and fungal pathogenesis. Expert Rev Anti Infect Ther. 2003 Jun; 1(1):167-73.
    View in: PubMed
  116. Marty F, Mylonakis E. . Use of antifungals in HIV infection. Expert Opin Pharmacother. 2003; 3:91-102.
  117. Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15675-80.
    View in: PubMed
  118. Feller AA, Mylonakis E, Rich JD. Medical complications of anabolic steroids. Med Health R I. 2002 Nov; 85(11):338-40.
    View in: PubMed
  119. Sifri CD, Mylonakis E, Singh KV, Qin X, Garsin DA, Murray BE, Ausubel FM, Calderwood SB. Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. Infect Immun. 2002 Oct; 70(10):5647-50.
    View in: PubMed
  120. Mylonakis E, Engelbert M, Qin X, Sifri CD, Murray BE, Ausubel FM, Gilmore MS, Calderwood SB. The Enterococcus faecalis fsrB gene, a key component of the fsr quorum-sensing system, is associated with virulence in the rabbit endophthalmitis model. Infect Immun. 2002 Aug; 70(8):4678-81.
    View in: PubMed
  121. Koutkia P, Mylonakis E, Levin RM. Human immunodeficiency virus infection and the thyroid. Thyroid. 2002 Jul; 12(7):577-82.
    View in: PubMed
  122. Mylonakis E, Paliou M, Hohmann EL, Calderwood SB, Wing EJ. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore). 2002 Jul; 81(4):260-9.
    View in: PubMed
  123. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis. 2002 May 15; 34(10):1337-41.
    View in: PubMed
  124. Marty F, Mylonakis E. Antifungal use in HIV infection. Expert Opin Pharmacother. 2002 Feb; 3(2):91-102.
    View in: PubMed
  125. Mylonakis E, Paliou M, Hohmann E, Calderwood SB, Wing EJ. . Listeriosis during pregnancy: a case series and review of 222 cases. 2002;81:260-9. Medicine [Baltimore]. 2002; 81:260-9.
  126. Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. . Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. 2002;99:15675-80. Proc Natl Acad Sci USA. 2002; 99:15675-80.
  127. Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation. 2001 Nov 27; 72(10):1587-92.
    View in: PubMed
  128. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001 Nov 1; 345(18):1318-30.
    View in: PubMed
  129. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, Calderwood SB, Ausubel FM. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10892-7.
    View in: PubMed
  130. Mylonakis E, Koutkia P, Grinspoon S. Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women. Clin Infect Dis. 2001 Sep 15; 33(6):857-64.
    View in: PubMed
  131. Mylonakis E. When to suspect and how to monitor babesiosis. Am Fam Physician. 2001 May 15; 63(10):1969-74.
    View in: PubMed
  132. Koutkia P, Mylonakis E, Rounds S, Erickson A. Cutaneous leucocytoclastic vasculitis associated with oxacillin. Diagn Microbiol Infect Dis. 2001 Mar; 39(3):191-4.
    View in: PubMed
  133. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile--Associated diarrhea: A review. Arch Intern Med. 2001 Feb 26; 161(4):525-33.
    View in: PubMed
  134. Mylonakis E, Paliou M, Rich JD. Plasma viral load testing in the management of HIV infection. Am Fam Physician. 2001 Feb 1; 63(3):483-90, 495-6.
    View in: PubMed
  135. Mylonakis E, Koutkia P, Grinspoon S. . Diagnosis and treatment of androgen deficiency in HIV-infected men and women. This article was included in “Current Topics in HIV Medicine: Using Basic Science to Inform Best Clinical Practices”, a compendium of HIV/AIDS-related articles published by the “HIV Medicine Association”. Clin Infect Dis. 2001; 33:857-64.
  136. Mylonakis E. . What is babesiosis?. [Patient information handout]. Am Fam Phys. 2001; 63:1975.
  137. Filbin MR, Mylonakis EE, Callegari L, Legome E. Babesiosis. J Emerg Med. 2001 Jan; 20(1):21-4.
    View in: PubMed
  138. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, Calderwood SB, Ausubel FM. . A simple model host for identifying gram-positive virulence factors. 2001;98:10892-7. Proc Natl Acad Sci USA. 2001; 98:10892-7.
  139. Gorbach SL, Falagas M, Mylonakis E, Stone D. . The 5-Minute Infectious Disease Consult. Lipincott Williams and Wilkins. 2001.
  140. Mylonakis E, Rich JD. Infectious Disease Trial Reviews. Infectious Disease Trial Reviews. 2001.
  141. Koutkia P, Mylonakis E, Erickson A, Rounds S. . Cutaneous leukocytoclastic vasculitis associated with oxacillin therapy. Diagn Microb Infect Dis. 2001; 39:191-4.
  142. Mylonakis E, Ryan ET, Calderwood SB. . Clostridium difficile-associated diarrhea. A review. Arch Intern Med. 2001; 161:525-33.
  143. Koutkia P, Mylonakis E, Rounds S, Erickson A. Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol. 2001; 30(6):315-22.
    View in: PubMed
  144. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000 Nov; 109(7):568-76.
    View in: PubMed
  145. Mylonakis E, Paliou M, Greenbough TC, Flaningan TP, Letvin NL, Rich JD. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med. 2000 Aug 14-28; 160(15):2386-8.
    View in: PubMed
  146. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore). 2000 Jul; 79(4):269-80.
    View in: PubMed
  147. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. . Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Medicine [Baltimore]. 2000; 79:269-80.
  148. Lopez FF, Mangi A, Mylonakis E, Chen JL, Schiffman FJ. Atrial fibrillation and tumor emboli as manifestations of metastatic leiomyosarcoma to the heart and lung. Heart Lung. 2000 Jan-Feb; 29(1):47-9.
    View in: PubMed
  149. Mylonakis E, Akhtar MS, Lopez F, Hussain I, Chen JL, Koutkia P, Lamberton P, Schiffman FJ. . Resolution of methimazole-induced agranulocytosis with human granulocyte colony stimulating factor (G-CSF). Geriatrics. 2000; 55:89-91.
  150. Mylonakis E, Feller AA, Salas CM, Rich JD. . Infectious and non-infectious complications of anabolic steroids in adults and adolescents. Am J Med Sports. 2000; 2:250-5.
  151. Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis. 1999 Aug; 34(4):325-7.
    View in: PubMed
  152. Mylonakis E, Merriman NA, Rich JD, Flanigan TP, Walters BC, Tashima KT, Mileno MD, van der Horst CM. Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diagn Microbiol Infect Dis. 1999 Jun; 34(2):111-4.
    View in: PubMed
  153. Rich JD, Dickinson BP, Flaxman AB, Mylonakis E. Local spread of molluscum contagiosum by electrolysis. Clin Infect Dis. 1999 May; 28(5):1171.
    View in: PubMed
  154. Mylonakis E, Mega A, Schiffman FJ. What do program directors in internal medicine think about international medical graduates? Results of a pilot study. Acad Med. 1999 Apr; 74(4):452.
    View in: PubMed
  155. Mylonakis E, Kon D, Moulton A, Elion J, Indeglia R, Koutkia P, Katz A. Thrombosis of mitral valve prosthesis presenting as abdominal pain. Heart Lung. 1999 Mar-Apr; 28(2):110-3.
    View in: PubMed
  156. Mylonakis E, Dickinson BP, Mileno MD, Flanigan T, Schiffman FJ, Mega A, Rich JD. Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. Am J Hematol. 1999 Feb; 60(2):164-6.
    View in: PubMed
  157. Mylonakis E, Koutkia P. . Research during residency letter. JAMA. 1999; 281:2088.
  158. Mylonakis E, Vittorio CC, Hollik D, Rounds S. . Lamotrigine toxicity presenting as anticonvulsant hypersensitivity syndrome. Ann Pharmacother. 1999; 33:557-9.
  159. Chodock R, Mylonakis E, Shemin D, Runasdottir V, Yodice P, Renzi R, Towe C, Rich JD. . Nucleoside associated lactic acidosis: Review and case report of survival with hemodialysis. Nephr Dial Transpl. 1999; 14:2484-6.
  160. Chang A, Mylonakis E, Karanasias P, De Orchis D, Gold R. . Spontaneous bilateral vertebral artery dissection. Case report and review. Mayo Clin Proc. 1999; 74:893-6.
  161. Rich JD, Mylonakis E, Flanigan TP. . Misdiagnosis of HIV-1 infection [letter]. Ann Intern Med. 1999; 131:547-8.
  162. Rich JD, Merriman NA, Mylonakis E, Greenough TC, Flanigan TP, Mady BJ, Carpenter CCJ. . The emergence of false positive HIV-1 plasma viral loads: a case series. Ann Intern Med. 1999; 130:37-9.
  163. Rich JD, Dickinson BP, Feller A, Pugatch D, Mylonakis E. . Infectious complications of anabolic steroids. . Int J Sports Med. 1999; 20:563-6.
  164. Grumbach N, Mylonakis E, Wing EJ. . Development of Listeria meningitis during ciprofloxacin therapy. Clin Infect Dis. 1999; 29:1340-1.
  165. Dickinson BP, Mylonakis E, Strong LL, Rich JD. . Potential infections related to anabolic steroid injection in young adolescents [letter]. Pediatrics 1999;103:694. 1999; 103:694.
  166. Mylonakis E. Do-not-resuscitate orders in radiology departments [letter]. . Letter. Ann Intern Med. 1999; 131:72-3.
  167. Rich JD, Mylonakis E, Nossa R, Chapnick RM. . Highly active antiretroviral therapy-associated resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Dig Dis Sci. 1999; 44:1034-7.
  168. Mylonakis E, Flanigan TP. Antifungal prophylaxis with weekly fluconazole for patients with AIDS. Clin Infect Dis. 1998 Dec; 27(6):1376-8.
    View in: PubMed
  169. Mylonakis E, Dickinson B, Feller A, Sweeney J, Schiffman FJ, Rich J, Flanigan T. Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV-infected individuals with anemia of chronic disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1; 19(3):306-7.
    View in: PubMed
  170. Dickinson BP, Mitty JA, Mylonakis E, Rich JD, Merriman NA, Tashima KT, Carpenter CC, Flanigan TP. Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care. AIDS. 1998 Oct 22; 12(15):2075-6.
    View in: PubMed
  171. Danias PG, Chalevelakis G, Mylonakis EE, Argyropoulou A, Paniara O, Saroglou G, Raptis SA. Comparative in vitro and in vivo efficacy of roxithromycin and erythromycin against a strain of methicillin-susceptible Staphylococcus epidermidis. Diagn Microbiol Infect Dis. 1998 Sep; 32(1):51-4.
    View in: PubMed
  172. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore). 1998 Sep; 77(5):313-36.
    View in: PubMed
  173. Danias P, Chalevelakis G, Mylonakis E, Saroglou G, Argyropoulou A, Paniara O, Raptis S. . Comparative in vitro and in vivo efficacy of roxithromycin and erythromycin against a strain of methicillin-susceptible Staphylococcus epidermidis. 1998;32:51-4. Diagn Microb Infect Dis. 1998; 32(51):4.
  174. Mylonakis E, Hohmann EL, Calderwood SB. . Central nervous system infection with Listeria monocytogenes: 33 years’ experience at a general hospital and review of 776 episodes from the literature. 1998;77:313-36. Medicine [Baltimore]. 1998; 77:313-36.
  175. Mylonakis E, Barlam TF, Flanigan T, Rich J. . Pulmonary aspergillosis in the acquired immunodeficiency syndrome: review of 342 cases. Chest The abstract and tables, accompanied by an editorial comment, were also published in the Year Book of Pulmonary Disease. 1998; 114:251-62.
  176. Mylonakis E, Koutkia P, Dickinson BP, Rich J, Flanigan T, Horwitz H. . Vasculitis and HIV. AIDS Reader. 1998; 8:192-3.
  177. Koutkia P, Mylonakis E, Flanigan T. . Cookouts and seasonal peak of Escherichia coli infection [letter]. Am Fam Physician. 1998; 57:1494.
  178. Mylonakis E, Mileno MD, Flanigan T, De Orchis D, Rich J. . Pulmonary invasive aspergillosis in HIV-infected patients. Report of two cases. Heart Lung. 1998; 27:63-6.
  179. Mylonakis E, Koutkia P, Rich JD, Tashima KT, Fiore TC, Flanigan T, Carpenter CCJ. . Substance abuse is responsible for most pre-AIDS deaths among women with HIV infection in Providence, RI, USA [letter]. AIDS. 1998; 12:958-9.
  180. Mylonakis E, Rich JD. . Update on the management of AIDS-related cytomegalovirus retinitis. Antibiotics for Clinicians. 1998; 2(5):86-7.
  181. Mylonakis E, Rich JD. . Laboratory diagnosis of toxoplasmosis in HIV-infected patients. Infectious Disease Practice. 1998; 22:99.
  182. Mylonakis E, Rich JD. . Laboratory diagnosis of cytomegalovirus infection in HIV-infected patients. Infectious Disease Practice. 1998; 22:88-9.
  183. Mylonakis E, Rich JD. . Management of toxoplasmosis in HIV-infected patients. Antibiotics for Clinicians. Antibiotics for Clinicians. 1998; 2(5):106.
  184. Mylonakis E, Chalevelakis G, Saroglou G, Danias P, Argyropoulou AD, Paniara O, Raptis SA. Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis. Mayo Clin Proc. 1997 Nov; 72(11):1022-7.
    View in: PubMed
  185. Mylonakis E, Nizam R, Freeman N. Periurethral abscess: complication of UTI. Geriatrics. 1997 Aug; 52(8):86-8.
    View in: PubMed
  186. Koutkia P, Mylonakis E, Flanigan T. . Enterohemorrhagic Escherichia coli O157:H7 [Patient information handout]. Am Fam Physician. 1997; 56:859-61.
  187. Mylonakis E, Rich J, Skolnik P, De Orchis D, Flanigan T. . Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Medicine [Baltimore]. 1997; 76(249):5.
  188. Koutkia P, Mylonakis E, Flanigan T. . Enterohemorrhagic Escherichia coli O157:H7 An emerging pathogen. Am Fam Physician. 1997; 56:853-9.
  189. Mylonakis E, Rich J, Kwakwa H, Flanigan T, De Orchis D, Boyce J, Mileno MD. . Muscle abscess due to Aspergillus fumigatus in an AIDS patient. Clin Infect Dis. 1996; 23:1323-4.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Mylonakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_